Fig. 3
From: Burden of asthma and COPD overlap (ACO) in Taiwan: a nationwide population-based study
Respiratory-related medication use in the 12 months following the index datea. aOnly medications prescribed to >1% of patients in at least two cohorts are presented. bAll comparisons with ACO were statistically significant (p ≤ 0.001) except for the use of oral systemic corticosteroids (≤14 days) between the ACO and COPD cohorts (p = 0.500). ACO, asthma-COPD overlap; COPD, chronic obstructive pulmonary disease; CS, corticosteroid; ICS, inhaled corticosteroid; IgE, immunoglobulin E; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; NS, not significant; SABA, short-acting β2-agonist; SABD, short-acting bronchodilator; SAMA, short-acting muscarinic antagonist; Sys, systemic